Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions-Reference-Cited by-同舟云学术

Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions

Published:2019-03-25 Issue:7 Volume:26 Page:953-960
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Ferreira J. J.¹²,Lees A.³,Rocha J.‐F.⁴^ORCID,Poewe W.⁵,Rascol O.⁶,Soares‐da‐Silva P.⁴⁷⁸

Affiliation:

1. Faculty of Medicine Instituto de Medicina Molecular University of Lisbon Lisbon Torres Vedras Portugal

2. CNS ‐ Campus Neurológico Sénior Torres Vedras Portugal

3. Reta Lila Weston Institute University College London London UK

4. Department of Research and Development BIAL – Portela & C^a SA S. Mamede do Coronado Portugal

5. Department of Neurology Medical University Innsbruck Innsbruck Austria

6. Clinical Investigation Centre CIC1436 Departments of Clinical Pharmacology and Neurosciences NS‐Park/FCRIN Network University Hospital of Toulouse INSERM University Toulouse 3 Toulouse France

7. Department of Pharmacology and Therapeutics Faculty of Medicine University Porto PortoPortugal

8. Center for Drug Discovery and Innovative Medicines MedInUP University Porto Porto Portugal

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.13914

Reference7 articles.

1. Ongentys.Summary of Product Characteristics2018. Available for download at:https://www.ema.europa.eu/documents/product-information/ongentys-epar-product-information_en.pdf(accessed 18/12/2018).

2. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial

3. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations

4. Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease

5. European Medicines Agency.Ongentys Assessment Report.2016. Procedure No. EMEA/H/C/002790/0000. Available for download at:https://www.ema.europa.eu/en/medicines/human/EPAR/ongentys(accessed 18/12/2018).

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson’s disease: pooled analysis of patient level data from two randomized open-label studies;Journal of Neurology;2024-08-21

2. OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2;Parkinsonism & Related Disorders;2024-06

3. Medical, surgical, and physical treatments for Parkinson's disease;The Lancet;2024-01

4. Management of OFF condition in Parkinson disease;Mental Health Clinician;2023-12-01

5. INVESTIGATION OF THE STRUCTURES OF CLINICALLY IMPORTANT CATECHOLAMINES AND THEIR DERIVATIVES;Ankara Universitesi Eczacilik Fakultesi Dergisi;2023-11-30